PE20131065A1 - Composiciones farmaceuticas combinadas y metodo de tratamiento del vertigo, la cinetosis y la distonia vegetativa-vascular - Google Patents

Composiciones farmaceuticas combinadas y metodo de tratamiento del vertigo, la cinetosis y la distonia vegetativa-vascular

Info

Publication number
PE20131065A1
PE20131065A1 PE2013000111A PE2013000111A PE20131065A1 PE 20131065 A1 PE20131065 A1 PE 20131065A1 PE 2013000111 A PE2013000111 A PE 2013000111A PE 2013000111 A PE2013000111 A PE 2013000111A PE 20131065 A1 PE20131065 A1 PE 20131065A1
Authority
PE
Peru
Prior art keywords
distonia
kinetosis
vegetative
vascular
treatment
Prior art date
Application number
PE2013000111A
Other languages
English (en)
Inventor
Oleg Iliich Epshtein
Original Assignee
Oleg Iliich Epshtein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44899157&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20131065(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from RU2010130353/15A external-priority patent/RU2542445C2/ru
Priority claimed from RU2010130356/15A external-priority patent/RU2542453C2/ru
Priority claimed from RU2011127052/15A external-priority patent/RU2503462C2/ru
Priority claimed from RU2011127058/15A external-priority patent/RU2536232C2/ru
Application filed by Oleg Iliich Epshtein filed Critical Oleg Iliich Epshtein
Publication of PE20131065A1 publication Critical patent/PE20131065A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: a) UNA FORMA ACTIADA-POTENCIADA DE ANTICUERPOS CONTRA LA PROTEINA S-100 ESPECIFICA DEL CEREBRO TAL COMO LA PROTEINA S-100 BOVINA QUE TIENE LAS SECUENCIAS SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:11 O SEQ ID NO:12 Y b) UNA FORMA ACTIVADA-POTENCIADA DE ANTICUERPOS CONTRA LA OXIDO NITRICO SINTASA (NOS) ENDOTELIAL TAL COMO NOS HUMANA. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE LA DISTONIA VEGETATIVA VASCULAR, LA CINETOSIS Y VERTIGO POR DIVERSAS CAUSAS
PE2013000111A 2010-07-21 2011-07-15 Composiciones farmaceuticas combinadas y metodo de tratamiento del vertigo, la cinetosis y la distonia vegetativa-vascular PE20131065A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
RU2010130353/15A RU2542445C2 (ru) 2010-07-21 2010-07-21 Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера
RU2010130356/15A RU2542453C2 (ru) 2010-07-21 2010-07-21 Лекарственное средство и способ лечения вегето-сосудистой дистонии, синдрома головокружения различного генеза и кинетозов
RU2011127052/15A RU2503462C2 (ru) 2011-07-01 2011-07-01 Способ лечения головокружения различного генеза, кинетозов и вегето-сосудистой дистонии (варианты) и лекарственное средство
RU2011127058/15A RU2536232C2 (ru) 2011-07-01 2011-07-01 Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера

Publications (1)

Publication Number Publication Date
PE20131065A1 true PE20131065A1 (es) 2013-09-23

Family

ID=44899157

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013000111A PE20131065A1 (es) 2010-07-21 2011-07-15 Composiciones farmaceuticas combinadas y metodo de tratamiento del vertigo, la cinetosis y la distonia vegetativa-vascular

Country Status (22)

Country Link
US (1) US20130058981A1 (es)
EP (1) EP2596018A2 (es)
JP (2) JP2013536174A (es)
KR (1) KR20130102542A (es)
CN (1) CN103124741A (es)
AR (1) AR082314A1 (es)
AU (1) AU2011281248B2 (es)
BR (1) BR112013001296A2 (es)
CA (1) CA2805985A1 (es)
CL (1) CL2013000201A1 (es)
DE (1) DE112011102397T5 (es)
EA (1) EA029998B1 (es)
ES (1) ES2446643R1 (es)
FR (1) FR2962910A1 (es)
GB (1) GB2496342B (es)
IL (1) IL224336A (es)
IT (1) ITTO20110630A1 (es)
MX (1) MX355371B (es)
NZ (1) NZ606988A (es)
PE (1) PE20131065A1 (es)
SG (2) SG187160A1 (es)
WO (1) WO2012010974A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
CN103154028A (zh) 2010-07-15 2013-06-12 奥列格·伊里奇·爱泼斯坦 复合药物组合物以及对神经退行性疾病相关的疾病或病症进行治疗的方法
SG187038A1 (en) * 2010-07-15 2013-02-28 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
MX361778B (es) 2010-07-15 2018-12-17 Oleg Iliich Epshtein Composiciones farmaceuticas y metodos de tratamiento.
CA2805978C (en) 2010-07-21 2016-06-28 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition
US20130058982A1 (en) * 2010-07-21 2013-03-07 Oleg Iliich Epshtein Method of treating Alzheimer's disease
MX2013000804A (es) * 2010-07-21 2013-10-28 Oleg Iliich Epshtein Una composicion de combinacion farmaceutica y metodos para tratar la diabetes y los trastornos metabolicos.
UA112755C2 (uk) 2010-07-21 2016-10-25 Олєг Ільіч Епштейн Метод лікування синдрому дефіциту уваги і гіперактивності
AU2011287292B2 (en) * 2010-08-06 2017-02-02 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
RU2013111962A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111961A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
RU2113230C1 (ru) 1996-04-03 1998-06-20 Ильчиков Михаил Захарович Седативное лекарственное средство "авиаморе"
US6150500A (en) * 1996-07-12 2000-11-21 Salerno; John C. Activators of endothelial nitric oxide synthase
US5849528A (en) * 1997-08-21 1998-12-15 Incyte Pharmaceuticals, Inc.. Polynucleotides encoding a human S100 protein
RU2156621C1 (ru) * 1999-03-04 2000-09-27 Эпштейн Олег Ильич Нейротропное лекарственное средство
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
AU2002258518A1 (en) * 2001-03-14 2002-09-24 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
RU2201255C1 (ru) * 2001-12-26 2003-03-27 Эпштейн Олег Ильич Лекарственное средство и способ регуляции сосудистого тонуса
UA76641C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
UA76639C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
CA2500687A1 (en) * 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
TWI345470B (en) 2003-03-14 2011-07-21 Nutrition Res Inc Homeopathic formulations useful for treating pain and/or inflammation
SG187038A1 (en) * 2010-07-15 2013-02-28 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
CN103154028A (zh) * 2010-07-15 2013-06-12 奥列格·伊里奇·爱泼斯坦 复合药物组合物以及对神经退行性疾病相关的疾病或病症进行治疗的方法
MX361778B (es) * 2010-07-15 2018-12-17 Oleg Iliich Epshtein Composiciones farmaceuticas y metodos de tratamiento.
MX2013000804A (es) * 2010-07-21 2013-10-28 Oleg Iliich Epshtein Una composicion de combinacion farmaceutica y metodos para tratar la diabetes y los trastornos metabolicos.
CA2805978C (en) * 2010-07-21 2016-06-28 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition
FR2962914A1 (fr) * 2010-07-21 2012-01-27 Oleg Iliich Epshtein Composition pharmaceutique destinee a etre utilisee dans un procede pour traiter les maladies organiques du systeme nerveux, le syndrome psycho-organique et l'encephalopathie
UA112755C2 (uk) * 2010-07-21 2016-10-25 Олєг Ільіч Епштейн Метод лікування синдрому дефіциту уваги і гіперактивності
US20130058982A1 (en) * 2010-07-21 2013-03-07 Oleg Iliich Epshtein Method of treating Alzheimer's disease

Also Published As

Publication number Publication date
CN103124741A (zh) 2013-05-29
SG187160A1 (en) 2013-02-28
US20130058981A1 (en) 2013-03-07
EP2596018A2 (en) 2013-05-29
IL224336A (en) 2017-06-29
NZ606988A (en) 2015-08-28
CL2013000201A1 (es) 2015-01-23
KR20130102542A (ko) 2013-09-17
AR082314A1 (es) 2012-11-28
JP2016199571A (ja) 2016-12-01
WO2012010974A8 (en) 2013-04-25
FR2962910A1 (fr) 2012-01-27
GB2496342B (en) 2017-12-06
GB201302925D0 (en) 2013-04-03
CA2805985A1 (en) 2012-01-26
BR112013001296A2 (pt) 2017-12-19
ES2446643A2 (es) 2014-03-10
AU2011281248A1 (en) 2013-03-14
JP2013536174A (ja) 2013-09-19
ES2446643R1 (es) 2015-03-06
EA029998B1 (ru) 2018-06-29
ITTO20110630A1 (it) 2012-01-22
WO2012010974A2 (en) 2012-01-26
GB2496342A (en) 2013-05-08
WO2012010974A3 (en) 2012-04-19
MX2013000805A (es) 2013-10-28
SG10201505676RA (en) 2015-08-28
DE112011102397T5 (de) 2013-05-08
AU2011281248B2 (en) 2017-02-02
EA201300127A1 (ru) 2013-12-30
MX355371B (es) 2018-04-17

Similar Documents

Publication Publication Date Title
PE20131065A1 (es) Composiciones farmaceuticas combinadas y metodo de tratamiento del vertigo, la cinetosis y la distonia vegetativa-vascular
PH12017500834A1 (en) Methods and formulations for treating vascular eye diseases
BR112013027500A2 (pt) liberação controlada de imunossupressores de nanotransportadores sintéticos
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
PE20140978A1 (es) Composicion farmaceutica solida que contiene amlodipina y losartan y el proceso para producirla
MX2021001169A (es) Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acético, composiciones, y usos de las mismas.
PE20151727A1 (es) Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c
PE20170908A1 (es) VARIANTES DE INTERFERON a2b
PE20151558A1 (es) Inhibidores tripeptidicos de la epoxicetona proteasa
IN2012DN02737A (es)
GB2496337A (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
BR112016022318A2 (pt) método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo
PE20220960A1 (es) Proteinas de variantes de secuencias de aminoacidos de cry1da1 activas para lepidopteros
SG10201811186XA (en) Purification of proteins
PE20170142A1 (es) Proteina de fusion que inhibe angiogenesis o crecimiento y uso de la misma
BR112016023498A2 (pt) composições para higiene bucal
UA107836C2 (uk) Метод лікування хвороби альцгеймера
MX2017002469A (es) Composiciones de matrices extracelulares.
EA201300132A1 (ru) Фармацевтическая композиция и методы лечения и профилактики заболеваний, вызванных вич или ассоциированных с вич
PH12018550008A1 (en) Selected amide of y-hydroxybutyric acid and uses thereof in the treatment of alcohol misuse
PE20160847A1 (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
MX2015016410A (es) Esteres de acidos oligo-hidroxicarboxilicos y uso de los mismos.
UA118653C2 (uk) Суперагоністи глікопротеїнового гормону тривалої дії
PE20160848A1 (es) Nuevo compuesto para el tratamiento de hipoglicemia severa

Legal Events

Date Code Title Description
FC Refusal